Euan Thomson, Ph.D., President and CEO of Accuray Incorporated stated: "Launching the Synchrony System represents a major advance in the technology of radiation treatments. The human body is a dynamic, moving organism, but traditional radiation treatment devices have a static approach to treatment delivery that is unable to compensate for the body's natural motion. The Synchrony System maximizes the benefits of the CyberKnife's robotic, image-guided capability to track tumours as they move, and now opens a new cancer market to radiosurgery."
The Synchrony System has been involved in vital treatment applications at the University of California, San Francisco for one year. David Larson, M.D., Ph.D., Professor of Radiation Oncology at the University of California, San Francisco (UCSF) Medical Center stated: "The Synchrony System represents true dynamic radiosurgery, the ability to irradiate targets accurately as they are moving. This is an extraordinary advance in extracranial radiosurgery because it allows physicians to use much tighter margins to treat tumours that move with breathing. More healthy tissue is spared because it is no longer necessary to use larger margins to compensate for movement of tumours. We have used the Synchrony System over the last year at our institution with promising results."
The Synchrony System has also had extensive applications at Boulder Community Hospital for two years. David Martin, M.D., Director of the Boulder Community Hospital CyberKnife Radiosurgery Programme, stated: "We have had great success using the Synchrony System to treat over 70 patients at our centre with tumours in areas such as the lung, pancreas, kidney and liver. Total clinical accuracy, as measured in end-to-end tests using a motion table, is remarkably similar to end-to-end testing done with a static tumour. The use of robotic compensation for respiratory movement is an important advancement: the greater accuracy allows us to use higher doses and complete treatment in a single session, compared to multiple treatments over several weeks required by conventional radiation therapy. We are just beginning to exploit the benefits of this exciting tool to more effectively treat thoracic and abdominal tumours."
The CyberKnife Stereotactic Radiosurgery System is a non-invasive, 100 percent frameless image-guided radiosurgery system that ablates tumours and other lesions anywhere in the body without open surgery. The CyberKnife System treats in single or staged, typically 2 to 5, sessions, and monitors internal reference points in the anatomy such as skeletal landmarks or small implanted markers, to correct for patient movement in real time during actual treatment. It delivers multiple beams of precisely directed radiation that converge upon the tumour while minimizing injury to surrounding healthy tissue. It is the only system in the world that integrates real-time image guidance and robotic delivery of radiation to deliver proven sub-millimeter "total clinical accuracy".
The unique CyberKnife technology was developed in co-operation with Stanford University and was FDA approved in August 2001. In September 2002, CyberKnife received CE approval to provide radiosurgery for lesions anywhere in the body when radiation treatment is indicated. To date, the CyberKnife System has treated over 8000 patients worldwide.
Accuray is a privately held corporation dedicated to revolutionizing the treatment of solid cancers anywhere in the body by the precise delivery of high doses of radiation using the CyberKnife Stereotactic Radiosurgery System. Through the development and marketing of its CyberKnife System, and participation in ongoing clinical research at prominent academic hospitals, Accuray helps make stereotactic radiosurgery a viable and accessible option for patients worldwide. More news on Cyberknife is available in the VMW June 2004 article Missile-guided CyberKnife weapon against pancreatic cancer now available in Miami